Jaypirca Shows Significant Efficacy in Advanced CLL/SLL Treatment

Eli Lilly announced positive Phase 3 trial results for pirtobrutinib (Jaypirca), demonstrating a 45% reduction in disease progression or death when added to a standard regimen for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. These findings will be presented at an upcoming European Hematology Association meeting. This represents a promising development for patients with these challenging blood cancers, potentially offering a new treatment option.